Mylotarg Infusion
gemtuzumab ozogamicin
4.5mg
Pfizer Inc.
| Pack size | 1 Amber Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 41002.50 AED |
Indications
Mylotarg Infusion is used for:
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of gemtuzumab ozogamicin :
Mechanism of Action
Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in site-specific DNA double strand breaks via formation of a p-benzene diradical [A20377]. Eventually, cell death is induced.
Note
Mylotarg 4.5mg Infusion manufactured by Pfizer Inc.. Its generic name is gemtuzumab ozogamicin. Mylotarg is availble in United Arab Emirates.
Farmaco UAE drug index information on Mylotarg Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.